Molecules, Madness, and Malaria: How Victorian Fabric Dyes Evolved into Modern Medicines for Mental Illness and Infectious Disease
In 1856, William Henry Perkin, an 18 year old chemistry student in London, was attempting to synthesize quinine, when instead he ended up with a dark sticky substance in the bottom of his test tube. When cleaning it out with alcohol, he produced a bright purple liquid, which became aniline purple, the first synthetic fabric dye, and inadvertently launched an industry. Within the next few years, about 30 companies appeared, using synthetic organic chemistry to make dyes, and later over the years paints, cosmetics, agricultural chemicals, food coloring—and medicines. Among these were medicines for psychiatry and infectious diseases, particularly malaria, which at the time was devastating the development of a worldwide empire. These efforts were not in isolation, but intertwined, culminating in the appearance in the 1950s of a failed antimalarial, chlorpromazine (Thorazine), which revolutionized care of psychotic patients. Sulfa drugs, derived from a red azo dye, became the building blocks on one of the trails to the first antidepressants. A penicillin preservative became meprobamate, the first blockbuster tranquilizer. Later, benzodiazepine tranquilizers were created from fabric dyes their inventor had previously discarded as a student.

The role of dye-derived synthetic drugs in medicine continues to this day, as indigo and related dyes are being developed for treating infections and cancer. Methylene blue, discovered 150 years ago, is now being studied for Alzheimer's disease. This story is as old as seventeenth century missionaries discovering medicinal leaves in the high Andes, and as new as today's headlines. In this book, Dr. Mendelson uses his 40 years of experience in pharmacology to describe the little-known history of the intertwined efforts to find treatments for psychiatric illness and infectious disease.
1137080931
Molecules, Madness, and Malaria: How Victorian Fabric Dyes Evolved into Modern Medicines for Mental Illness and Infectious Disease
In 1856, William Henry Perkin, an 18 year old chemistry student in London, was attempting to synthesize quinine, when instead he ended up with a dark sticky substance in the bottom of his test tube. When cleaning it out with alcohol, he produced a bright purple liquid, which became aniline purple, the first synthetic fabric dye, and inadvertently launched an industry. Within the next few years, about 30 companies appeared, using synthetic organic chemistry to make dyes, and later over the years paints, cosmetics, agricultural chemicals, food coloring—and medicines. Among these were medicines for psychiatry and infectious diseases, particularly malaria, which at the time was devastating the development of a worldwide empire. These efforts were not in isolation, but intertwined, culminating in the appearance in the 1950s of a failed antimalarial, chlorpromazine (Thorazine), which revolutionized care of psychotic patients. Sulfa drugs, derived from a red azo dye, became the building blocks on one of the trails to the first antidepressants. A penicillin preservative became meprobamate, the first blockbuster tranquilizer. Later, benzodiazepine tranquilizers were created from fabric dyes their inventor had previously discarded as a student.

The role of dye-derived synthetic drugs in medicine continues to this day, as indigo and related dyes are being developed for treating infections and cancer. Methylene blue, discovered 150 years ago, is now being studied for Alzheimer's disease. This story is as old as seventeenth century missionaries discovering medicinal leaves in the high Andes, and as new as today's headlines. In this book, Dr. Mendelson uses his 40 years of experience in pharmacology to describe the little-known history of the intertwined efforts to find treatments for psychiatric illness and infectious disease.
6.99 In Stock
Molecules, Madness, and Malaria: How Victorian Fabric Dyes Evolved into Modern Medicines for Mental Illness and Infectious Disease

Molecules, Madness, and Malaria: How Victorian Fabric Dyes Evolved into Modern Medicines for Mental Illness and Infectious Disease

by Wallace B. Mendelson
Molecules, Madness, and Malaria: How Victorian Fabric Dyes Evolved into Modern Medicines for Mental Illness and Infectious Disease

Molecules, Madness, and Malaria: How Victorian Fabric Dyes Evolved into Modern Medicines for Mental Illness and Infectious Disease

by Wallace B. Mendelson

eBook

$6.99 

Available on Compatible NOOK devices, the free NOOK App and in My Digital Library.
WANT A NOOK?  Explore Now

Related collections and offers

LEND ME® See Details

Overview

In 1856, William Henry Perkin, an 18 year old chemistry student in London, was attempting to synthesize quinine, when instead he ended up with a dark sticky substance in the bottom of his test tube. When cleaning it out with alcohol, he produced a bright purple liquid, which became aniline purple, the first synthetic fabric dye, and inadvertently launched an industry. Within the next few years, about 30 companies appeared, using synthetic organic chemistry to make dyes, and later over the years paints, cosmetics, agricultural chemicals, food coloring—and medicines. Among these were medicines for psychiatry and infectious diseases, particularly malaria, which at the time was devastating the development of a worldwide empire. These efforts were not in isolation, but intertwined, culminating in the appearance in the 1950s of a failed antimalarial, chlorpromazine (Thorazine), which revolutionized care of psychotic patients. Sulfa drugs, derived from a red azo dye, became the building blocks on one of the trails to the first antidepressants. A penicillin preservative became meprobamate, the first blockbuster tranquilizer. Later, benzodiazepine tranquilizers were created from fabric dyes their inventor had previously discarded as a student.

The role of dye-derived synthetic drugs in medicine continues to this day, as indigo and related dyes are being developed for treating infections and cancer. Methylene blue, discovered 150 years ago, is now being studied for Alzheimer's disease. This story is as old as seventeenth century missionaries discovering medicinal leaves in the high Andes, and as new as today's headlines. In this book, Dr. Mendelson uses his 40 years of experience in pharmacology to describe the little-known history of the intertwined efforts to find treatments for psychiatric illness and infectious disease.

Product Details

BN ID: 2940184778327
Publisher: Pythagoras Press
Publication date: 12/21/2024
Sold by: Barnes & Noble
Format: eBook
File size: 20 MB
Note: This product may take a few minutes to download.

About the Author

Wallace Mendelson, MD, is Professor of Psychiatry and Clinical Pharmacology (ret.) at the University of Chicago. He is a Distinguished Fellow of the American Psychiatric Association, and a member of the American Academy of Neuropsychopharmacology. He has been director of the Section on Sleep Studies at the National Institute of Mental Health, the Sleep Disorders Center at the Cleveland Clinic Foundation, and the Sleep Research Laboratory at the University of Chicago. His publications include sixteen books and numerous professional papers. He is currently a Fellow of the Faculty of History and Philosophy of Medicine and Pharmacy at the Worshipful Society of Apothecaries, London. Among his honors have been the Academic Achievement Award from the American Sleep Disorders Association in 1999 and a special award for excellence in sleep and psychiatry from the National Sleep Foundation in 2010. More information about Dr. Mendelson’s work and a list of his books are available on Wikipedia and his website.
From the B&N Reads Blog

Customer Reviews